Clinical Trials Logo

Persistent Depressive Disorder clinical trials

View clinical trials related to Persistent Depressive Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT03616665 Not yet recruiting - Clinical trials for Persistent Depressive Disorder

Effectiveness of a Personalized Inpatient Program for Persistent Depressive Disorder

PePsy
Start date: November 20, 2018
Phase: N/A
Study type: Interventional

The major objective of this randomized controlled study is to compare a new conceptualized personalized concept of Cognitive Behavioral Analysis System of Psychotherapy (CBASPersonalized) with a six-week waiting-list control (WLC) group and a version of Cognitive Behavioral Therapy (CBIntegrative) in the treatment of patients with persistent depressive disorder (PDD), childhood maltreatment, and treatment-resistance. Both active groups will be offered as treatment-phase programs (six-week inpatient-treatment and optional six-week blended-online-aftercare) in combination with standardized pharmacotherapy in a routine clinical inpatient setting. This study addresses the primary research question: Is the intensive six-week inpatient CBASPersonalized treatment more effective than a six-week WLC in a clinical sample of PDD patients? In addition, CBASPersonalized will be compared with CBIntegrative investigating differential indication by moderator, mediator, and process analyses.

NCT ID: NCT02752542 Recruiting - Clinical trials for Major Depressive Disorder

Personalized Indications for CBT and Antidepressants in Treating Depression

CANBIND6
Start date: October 31, 2016
Phase: Phase 4
Study type: Interventional

Depression currently affects close to 2 million Canadians and is the leading cause of disability worldwide. Pharmacological treatments (antidepressant medication) and psychological treatments such as cognitive-behavioural therapy are available for depression, but the majority of those who receive treatment have an unsatisfactory response. On average, the combination of pharmacological and psychological treatment achieves better results than either treatment alone. However, the apparently superior results of combination treatment may be due to the fact that different individuals preferentially respond to pharmacological or psychological treatment. The invesitagtors have discovered several clinical factors and biomarkers that predict poor response to commonly used antidepressant medication: history of childhood maltreatment, loss of interest and reduced activity, a biomarker of systemic inflammation, and a genetic marker of sensitivity to environment. Indirect evidence suggests that the same factors may indicate the need for psychological treatment, but their usefulness as differential predictors of psychological and pharmacological treatment outcomes remains to be established. The investigators will test the hypothesis that a pre-determined set of clinical variables (history of childhood maltreatment, loss of interest and reduced activity) and biomarkers (serum C-reactive protein, a marker of systemic inflammation, and short alleles of the serotonin transporter gene promoter polymorphism) differentially predicts response to antidepressants and to cognitive-behavioural psychotherapy with clinically significant accuracy. If this hypothesis is supported, the resulting predictor will allow personalized selection of treatment for depression, leading to improved outcomes and healthcare efficiency. Additional objectives include replication of additional predictors and integrative analyses aimed at refining the treatment choice algorithms.

NCT ID: NCT01947647 Active, not recruiting - Clinical trials for Major Depressive Disorder

Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders

TBT-RCT
Start date: November 17, 2014
Phase: N/A
Study type: Interventional

Cognitive behavioral therapy (CBT) is a brief, efficient, and effective psychotherapy for individuals with depressive and anxiety disorders. However, CBT is largely underutilized within Veteran Affairs Medical Centers (VAMCs) due to the cost and burden of trainings necessary to deliver the large number of CBT protocols. Transdiagnostic CBT, in contrast, is specifically designed to address numerous distinct disorders within a single protocol. This transdiagnostic approach has the potential to dramatically improve the accessibility of CBT within VAMCs and therefore improve clinical outcomes of Veterans. The proposed research seeks to evaluate the efficacy of a transdiagnostic CBT by assessing clinical outcomes and quality of life in VAMC patients with depressive and anxiety disorders throughout the course of treatment and in comparison to an existing evidence-based psychotherapy, behavioral activation treatment.